EGFR and non-small cell lung carcinoma: The importance of the EGFR signaling pathway already led to the approval of several therapeutics, which are based either on monoclonal antibodies, such as cetuximab and panitumumab, or on small-molecule inhibitors such as gefitinib, erlotinib or afatinib, especially in the treatment of EGFR-mutated NSCLC [17, 18].